Estrigenix Therapeutics, Inc. is a privately held pharmaceutical company developing the next generation of innovative therapies for improving the mental health of menopausal women. Menopause is associated with cognitive dysfunction, increased mood and anxiety disorders, and an elevated risk of Alzheimer’s disease, yet standard estrogen therapies are associated with increased risks of cancer, heart disease, and stroke. Our mission is to develop novel drugs that mitigate the adverse effects of menopause on mental health and enable women to live healthier and happier lives.
The drug development program at Estrigenix focuses on selectively activating specific estrogen receptor proteins that promote memory formation, improve mood, and reduce anxiety. We believe that targeting these receptors will provide the cognitive and mood-enhancing benefits of estrogens without the harmful side effects of standard estrogen therapies.
Our lead compound, EGX-358, is a potent and selective agonist of the estrogen receptor beta protein, which enhances memory formation in a mouse model of menopause. Current work is expanding the use of this compound to other indications, including depression, anxiety, and hot flashes.
The drug development program at Estrigenix focuses on selectively activating specific estrogen receptor proteins that promote memory formation, improve mood, and reduce anxiety. We believe that targeting these receptors will provide the cognitive and mood-enhancing benefits of estrogens without the harmful side effects of standard estrogen therapies.
Our lead compound, EGX-358, is a potent and selective agonist of the estrogen receptor beta protein, which enhances memory formation in a mouse model of menopause. Current work is expanding the use of this compound to other indications, including depression, anxiety, and hot flashes.
Location: United States
Employees: 1-10
Total raised: $2M
Founded date: 2018
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.07.2026 | Seed | $2M | - |
Mentions in press and media 11
| Date | Title | Description |
| 27.07.2026 | Estrigenix Therapeutics Secures $2M Seed Funding for ERβ Innovation | Estrigenix Therapeutics, a Milwaukee biotech innovator, just closed a $2M seed funding round. Talents Fund I led the investment. This capital accelerates selective estrogen receptor-beta (ERβ) therapeutic development. The company targets cr... |
| 27.07.2026 | Estrigenix reaches commercialization milestones | In 2018, Milwaukee researchers launched Estrigenix Therapeutics to commercialize a novel menopause therapy. Recently, the company has reached two milestones that position it for its next phase of development. The biotechnology startup secur... |
| 21.07.2026 | Estrigenix Therapeutics Raises $2M in Seed Funding | Estrigenix Therapeutics, a Milwaukee, WI-based biotechnology company developing selective estrogen receptor-beta therapeutics, raised $2M in Seed funding. The round was led by Talents Fund I. The company intends to use the funds to support ... |
| 21.07.2026 | Estrigenix Therapeutics Raises $2 Million Series Seed To Advance ERβ Platform | Estrigenix Therapeutics has completed the first closing of a $2 million Series Seed financing to advance its selective estrogen receptor-beta platform. Talents Fund I led the round. The Milwaukee-based biotechnology company will use the fun... |
| 21.07.2026 | Sila Raises $300M in Private Equity Funding | Sila, an Alameda, CA-based battery technology company, raised $300M in a private equity funding. The round was led by Atreides Management, and Sutter Hill Ventures with participation 8VC, Bessemer Venture Partners, Matrix Partners, T. Rowe ... |
| 08.07.2026 | Estrigenix Therapeutics Secures Exclusive License Agreement for Novel Menopause Therapeutics Platform | Estrigenix Therapeutics, Inc., together with the University of Wisconsin–Milwaukee Research Foundation, Inc. (UWMRF), Marquette University, and CU Ventures, Inc., today announced the execution of an exclusive license agreement supporting th... |
| 03.02.2026 | Forward BIOLABS announces first ICP awardees | Forward BIOLABS has announced the first round of awardees for its Innovation to Commercialization Pipeline (ICP) program, a new initiative designed to help early-stage biohealth companies across Wisconsin move closer to market readiness. Th... |
| 24.11.2024 | Healthcare Innovation Pitch Competition 2024 | The sixth annual Healthcare Innovation Pitch Competition was presented by Bridge to Cures, the Medical College of Wisconsin’s Clinical and Translational Sciences Institute (CTSI) and Accelerating Medical Product Development (AMPDNR) and hos... |
| 25.03.2022 | Startup that aims to prevent tissue adhesions after surgery wins inaugural Apis health competition | From top left, clockwise: Apis fund manager Allen Nieman, MC Jolene Anderson, and Karios CEO Gregory Grover. (Apis Image) Houston-based Karios Technologies won the inaugural Apis Health Angel Conference, launched in Seattle to connect inves... |
| 24.11.2021 | Breakthrough estrogen discovery in Milwaukee | Approximately 6.2 million Americans are living with Alzheimer’s Disease, which is the leading cause of dementia. The two key risk factors in the development of Alzheimer’s Disease are age and sex. According to the Alzheimer’s Association, n... |
Show more